Neuro-Bio is a privately-owned biotech company based in Oxford University, specializing in the discovery of oral drugs for the treatment of Alzheimer's disease. They have a therapeutic focus on neurodegenerative diseases and have made significant discoveries in this field. The company has developed a unique peptide called T14, derived from the C terminus of AChE, which has proven to be neurotoxic and a potential key driver of neurodegeneration.

This groundbreaking finding has paved the way for the development of exciting new drugs to treat Alzheimer's disease. In addition to drug development, Neuro-Bio is also developing a biomarker test to measure T14 levels in blood. This companion diagnostic can help in the early detection and monitoring of Alzheimer's disease.

Neuro-Bio's disruptive approach has led to the identification of vulnerable cells, the explanation of their degeneration, and the discovery of T14 as a toxic peptide driving this process. They have developed a novel animal model and designed a T14 blocker as a therapeutic drug. The work of Neuro-Bio has been highly regarded by experts in the field, including Dr.

Richard Mohs, Chief Scientific Officer for the Global Alzheimer's Platform (GAP) Foundation. Neuro-Bio's dedication to advancing the understanding and treatment of Alzheimer's disease has attracted renowned professionals in the field, such as Professor Paul L Herrling, who recently joined their board. With the potential to address a major medical need, Neuro-Bio's innovative approach offers hope for a breakthrough in Alzheimer's treatment